Articles published by BeiGene![]() ![]() ![]() ![]() ![]() ![]()
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
April 27, 2022
From BeiGene
Via Business Wire
Tickers
BGNE
![]() ![]() ![]() ![]()
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
April 15, 2022
From BeiGene
Via Business Wire
Tickers
BGNE
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]()
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
December 10, 2021
From BeiGene
Via Business Wire
Tickers
BGNE
![]() ![]() ![]() ![]()
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339
November 22, 2021
From BeiGene
Via Business Wire
Tickers
BGNE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|